Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PPARA variant rs1800234 had a dose dependent pharmacogenetics impact on the therapeutic response to chiglitazar.

Pharmacogenomics - 1 Jan 2024

Geng Zhaoxu, Zheng Yuanting, Li Qian, Pan Desi, Lu Xianping, Chen Fei, Zhang Ying, Li Keying, Zhou Kaixin, Shi Leming, Wang You

Abstract excerpt

BACKGROUND: Our objective was to explore the pharmacogenetic impact of three known functional variants in drug target genes and determine whether they can explain the inter-individual variation in therapeutic response. METHODS: In a post hoc analysis of data from randomized controlled clinical trials of chiglitazar, we genotyped 481 Chinese patients with T2DM and investigated the association of variants in PPAR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Alleles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to East Asian People

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Share to PPAR alpha

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 39555806
DOI: 10.1080/14622416.2024.2430163
PMCID: PMC11703419

Genes

PPARA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PPARA variant rs1800234 had a dose dependent pharmacogenetics impact on the therapeutic response to chiglitazar.PMID 39555806Read ↗

Genetics: Response to antidiabetic drugs affected by SNPs that alter genomic binding of PPARγ.Semantic proximity Read ↗

Sequence variation in PPARG may underlie differential response to troglitazone.Semantic proximity Read ↗

Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology.Semantic proximity Read ↗

Adiponectin gene polymorphism rs2241766 T/G is associated with response to pioglitazone treatment in type 2 diabetic patients from southern China.Semantic proximity Read ↗

A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar.Semantic proximity Read ↗

Pharmacogenomics and Pharmacogenetics of Thiazolidinediones: Role in Diabetes and Cardiovascular Risk FactorsSemantic proximity Read ↗

Novel insulin sensitizers: pharmacogenomic aspects.Semantic proximity Read ↗

Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.Semantic proximity Read ↗

Pharmacogenetics of thiazolidinedione therapy.Semantic proximity Read ↗

Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes.Semantic proximity Read ↗

Association between glucagon-like peptide-1 receptor gene polymorphism and treatment response to GLP1R agonists in Chinese patients with type 2 diabetes: a prospective cohort studySemantic proximity Read ↗

PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms affect therapeutic efficacy of nateglinide in Chinese patients with type 2 diabetes mellitus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.